Home » Stocks » VVOS

Vivos Therapeutics, Inc. (VVOS)

Stock Price: $7.53 USD -0.46 (-5.76%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $7.40 -0.13 (-1.73%) Jan 15, 7:19 PM
Market Cap 129.92M
Revenue (ttm) 12.84M
Net Income (ttm) -10.71M
Shares Out 17.25M
EPS (ttm) -0.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $7.53
Previous Close $7.99
Change ($) -0.46
Change (%) -5.76%
Day's Open 7.79
Day's Range 7.35 - 7.99
Day's Volume 263,642
52-Week Range 5.91 - 9.11

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 1 week ago

Cyclo Therapeutics (NASDAQ: CYTH) shares are trading higher Tuesday after the company announced "positive" efficacy data from an extension protocol with Trappsol Cyclo in patients with Niemann...

Other stocks mentioned: MRKR, THC, CYTH
GlobeNewsWire - 1 month ago

HIGHLANDS RANCH, Colo., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos”) today announced the closing of its initial public offering of 4,025,000 shares of its common stock....

GlobeNewsWire - 1 month ago

HIGHLANDS RANCH, Colo., Dec. 10, 2020 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“ Vivos ”), a medical technology company that offers novel and proprietary alternatives for treating mild-to...

GlobeNewswire - 3 months ago

Vivos Therapeutics, Inc., a medical technology company that offers novel and proprietary alternatives for treating mild-to-moderate obstructive sleep apnea, today announced that is has filed a...

SEC - 3 months ago

Vivos Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ stock exchange.

About VVOS

Vivos Therapeutics, a medical technology company, engages in the development and commercialization of technology solutions for patients with sleep disordered breathing (SDB) comprising mild-to-moderate obstructive sleep apnea (OSA). The company's solutions cover proprietary alternatives for treating mild-to-moderate OSA; craniofacial and anatomical anomalies that are associated with mild-to-moderate OSA. Its treatment for OSA involves specially designed and customized oral appliances and treatment protocols. The company, through its Vivos Integ... [Read more...]

Industry
Medical Devices
IPO Date
Dec 11, 2020
CEO
R. Kirk Huntsman
Employees
92
Stock Exchange
NASDAQ
Ticker Symbol
VVOS
Full Company Profile

Financial Performance

In 2019, VVOS's revenue was $11.39 million, an increase of 200.43% compared to the previous year's $3.79 million. Losses were -$10.75 million, 27.4% more than in 2018.

Financial Statements

Analyst Forecasts

According to one analyst, the rating for VVOS stock is "Buy" and the 12-month stock price forecast is 12.00.

Price Target
$12.00
Analyst Consensus: Buy